Stemming from this finding, a phase I clinical trial is addressing the safety, tolerability and efficacy of erdafitinib (NCT03238196) combined with ET and CDK4/6i in metastatic HR+/HER2− BC patients who progressed on first-line therapy with ET and CDK4/6i, with FGFR amplification. Here, CDK4 is linked to breast cancer.